Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Disparities in treatment timing and access to care in chronic lymphoytic leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

TGTomás Escobar Gil

Discussion

Loading...

Member takes

Overview

Scoping review reveals treatment timing disparities in chronic lymphocytic leukemia, highlighting health disparities based on race and socioeconomic status.

Key Points

  • This review examines disparities in treatment timing and access to care for chronic lymphocytic leukemia (CLL).
  • Conducted a scoping review of studies published from 2015 to 2025 on CLL treatment access.
  • Followed PRISMA guidelines for database searches including PubMed, EMBASE, COCHRANE, and Medline.
  • Included studies that addressed factors like treatment initiation, health disparities, and socioeconomic status.
  • Included five studies with 102,994 adult CLL patients, primarily from national datasets.
  • Found racial disparities in treatment timing and diagnosis age; Black patients had higher risks at younger ages.
  • Demonstrated socioeconomic factors influenced access, with lower income linked to delayed treatment.

Cite This Study

Tomás Escobar Gil (2025) studied this question.

synapsesocial.com/papers/69362f484fa91c937236d746https://doi.org/10.1182/blood-2025-8107
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Racial and ethnic disparities in u.S. chronic lymphocytic leukemia clinical trial enrollment: A participation-to-prevalence analysis2025 · 1 citations
  2. 2Access to care and survival outcomes in older adults with chronic lymphocytic leukemia/small lymphocytic lymphoma: A National Cancer Database study.2026
  3. 3Social determinants of health and long-term survival in chronic lymphocytic leukemia/small lymphocytic lymphoma: A population-based analysis of 118,667 patients2025
  4. 4Inequities in timely treatment (Tx) initiation for patients (pts) with acute myeloid leukemia (AML) treated in a predominantly community setting in the United States (US).2024
  5. 5Chronic myelogenous leukemia: A real-world experience from a Los Angeles county safety net hospital2025